Page 49 - 南京医科大学自然版
P. 49

第46卷第6期             朱天帆,陈     峰,黄惠结. SMOC2促进低氧诱导的肺血管平滑肌细胞表型转换[J].
                  2026年6月                      南京医科大学学报(自然科学版),2026,46(6):820-831                      ·831  ·


                   作者贡献声明:                                             catenin pathway modulation and inducing angiogene⁃
                   朱天帆负责实验方法设计、实验操作、实验数据收集与                            sis[J]. Clin Exp Med,2025,25(1):372
                分析;黄惠结负责研究构思、协助数据分析、论文初稿撰写及                      [12]FANG J D,CHEN H Y,JIA Z Z,et al. miRNAs in pulmo⁃
                修订,提供研究资金支持;陈峰负责研究构思、研究课题监管                            nary hypertension:mechanistic insights and therapeutic
                与指导、论文审阅与修订。                                           potential[J]. Biomedicines,2025,13(8):1910
                   Author’s Contributions:                       [13]POLINI B,GHELARDONI S,CAPONE G,et al. Circulat⁃
                   ZHU Tianfan was responsible for methodology,investigation  ing microRNAs in pulmonary arterial hypertension :
                and analysis. HUANG Huijie was responsible for methodology,  biomarkers for diagnosis,prognostic stratification,and
                investigation,data curation,analysis,writing and revising original  treatment[J]. GeroScience,2026,48(2):2243-2266
                draft,funding acquisition. CHEN Feng was responsible for concep  [14] XU J H,LINNEMAN J,ZHONG Y F,et al. MicroRNAs
                tualization,supervision,writing,reviewing and revising the  in pulmonary hypertension,from pathogenesis to diagnosis
                manuscript.                                            and treatment[J]. Biomolecules,2022,12(4):496
               [参考文献]                                            [15]LI Y,REN W D,WANG X,et al. MicroRNA⁃150 relieves
                                                                       vascular remodeling and fibrosis in hypoxia ⁃ induced
               [1] GHOFRANI H A,GOMBERG⁃MAITLAND M,ZHAO L,
                                                                       pulmonary hypertension[J]. Biomed Pharmacother,2019,
                    et al. Mechanisms and treatment of pulmonary arterial
                                                                       109:1740-1749
                    hypertension[J]. Nat Rev Cardiol,2025,22(2):105-120
                                                                 [16]RUSSOMANNO G,JO K B,ABDUL⁃SALAM V B,et al.
               [2] MOCUMBI A,HUMBERT M,SAXENA A,et al. Pulmo⁃
                                                                       miR ⁃ 150 ⁃ PTPMT1 ⁃ cardiolipin signaling in pulmonary
                    nary hypertension[J]. Nat Rev Dis Primers,2024,10:1
                                                                       arterial hypertension[J]. Mol Ther Nucleic Acids,2021,
               [3] MU T T,GUO B S,XIANG C Q,et al. Hypoxic microenvi⁃
                                                                       23:142-153
                    ronment and pulmonary hypertension[J]. Respir Res,
                                                                 [17] HWANG S J,AHN B J,SHIN M W,et al. miR⁃125a⁃5p
                    2025,27(1):22
                                                                       attenuates macrophage⁃mediated vascular dysfunction by
               [4] NAVARRO⁃LLINARES L,GARCÍA⁃LEN B,DE LA
                                                                       targeting Ninjurin1[J]. Cell Death Differ,2022,29(6):
                    BASTIDA⁃CASERO L,et al. The vascular⁃immune cells
                                                                       1199-1210
                    crosstalk and microenvironment in pulmonary hyperten⁃
                                                                 [18]WANG L N,REN L,LI L,et al. Role of SMOC2 in adeno⁃
                    sion[J]. Compr Physiol,2026,16:e70110
                                                                       myosis:implications for ECM remodeling and EMT patho⁃
               [5] BOUCHERAT O,BONNET S,PROVENCHER S,et al.
                                                                       genesis[J]. BMC Women’s Health,2025,25(1):155
                    Anti⁃remodeling therapies in pulmonary arterial hyperten⁃
                                                                 [19] HE Y R,PAN X D,LIU Z Y,et al. METTL3 silencing
                    sion[J]. Trends Pharmacol Sci,2025,46(7):674-691
                                                                       suppresses cardiac fibrosis post myocardial infarction
               [6] ADU⁃AMANKWAAH J,SHI Y,SONG H Q,et al. Signal⁃
                                                                       via m6A modification of SMOC2[J]. J Cellular Molecular
                    ing pathways and targeted therapy for pulmonary hyper⁃
                                                                       Medi,2025,29(17):e70829
                    tension[J]. Sig Transduct Target Ther,2025,10:207
                                                                 [20]WANG Y B,YANG H K,SU X,et al. TGF⁃β1/SMOC2/
               [7] TAKAHATA Y,URUSHIZAKI M,WAKAMORI K,et al.
                                                                       AKT and ERK axis regulates proliferation,migration,and
                    The Runx2⁃SMOC axis in skeletal development:expanding
                                                                       fibroblast to myofibroblast transformation in lung fibro⁃
                    roles of Smoc1 and Smoc2 in development and disease[J].
                                                                       blast,contributing with the asthma progression[J]. Here⁃
                    J Oral Biosci,2026,68(1):100738
                                                                       ditas,2021,158(1):47
               [8] WANG X W,WANG M,ZHOU Z X,et al. SMOC2 promot⁃
                    ed vascular smooth muscle cell proliferation,migration,  [21]REN Y,WU Y,HE W S,et al. SMOC2 plays a role in
                                                                       heart failure via regulating TGF⁃β1/Smad3 pathway⁃medi⁃
                    and extracellular matrix degradation by activating BMP/
                    TGF ⁃ β1 signaling pathway[J]. J Clin Biochem Nutr,  ated autophagy[J].Open Med,2023,18:20230752
                    2023,73(2):116-123                           [22]KUDRYASHOVA T V,GONCHAROV D A,PENA A,et al.
               [9] CHEN X,ZHONG X,LUO D,et al. Plasma SMOC2 pre⁃       HIPPO⁃integrin⁃linked kinase cross⁃talk controls self⁃sus⁃
                    dicts prognosis in patients with heart failure:a prospec⁃  taining proliferation and survival in pulmonary hyperten⁃
                    tive cohort[J]. Int J Gen Med,2024,17:1651⁃1664    sion[J]. Am J Respir Crit Care Med,2016,194(7):866⁃877
               [10] WILK J B,HERBERT A,SHOEMAKER C M,et al.      [23]GAO R J,AIKEREMU N,CAO N,et al. Quercetin regu⁃
                     Secreted modular calcium ⁃ binding protein 2 haplotypes  lates pulmonary vascular remodeling in pulmonary hyper⁃
                     are associated with pulmonary function[J]. Am J Respir  tension by downregulating TGF⁃β1⁃Smad2/3 pathway[J].
                     Crit Care Med,2007,175(6):554-560                 BMC Cardiovasc Disord,2024,24(1):535
               [11] LI C Q,YIN L X,ZHAO D Q,et al. SMOC2 promotes  (收稿:2026-03-02;修回:2026-04-22;录用:2026-04-23)
                     peritoneal metastasis of gastric cancer involving Wnt/β⁃                   (本文编辑:戴王娟)
   44   45   46   47   48   49   50   51   52   53   54